In bladder cancer, common alterations like FGFR3-TACC3 fusions and gain-of-function mutations (e.g., S249C, R248C) lead to hyperactivation of FGFR3 signaling, promoting tumor growth and progression [42]. The gene discussed is FGFR3; the disease is neoplasm.